Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 9/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385625 | 0.88 | MEN1 (0.40) | MEN1GFERKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL30963578 | 0.88 | MEN1 (0.40) | MEN1GFERKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL25187642 | 0.85 | POLB (0.35) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31019964 | 0.85 | POLB (0.35) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31019967 | 0.81 | ERN1 (0.40) | MEN1KMT2AHTR2AHTR2CKDM4E | |
| SCHEMBL25199320 | 0.81 | ERN1 (0.40) | MEN1KMT2AHTR2AHTR2CKDM4E | |
| SCHEMBL20530219 | 0.81 | MEN1 (0.42) | MEN1GFERKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL31019956 | 0.81 | PTGS2 (0.35) | — | |
| SCHEMBL18196882 | 0.80 | HTR6 (0.39) | MEN1GFERKMT2ASMN1; SMN2HTR6 | |
| Hydrochloric Acid SCHEMBL20530218 | 0.79 | HTR6 (0.39) | MEN1GFERKMT2ASMN1; SMN2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197867-B1 | NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | GIPR, GRPR, HTR3E | MEN1 3885/4885GFER 1379/4885KMT2A 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.